These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 31099694)

  • 1. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden.
    Santomasso B; Bachier C; Westin J; Rezvani K; Shpall EJ
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():433-444. PubMed ID: 31099694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
    Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
    J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive therapy with CAR redirected T cells for hematological malignancies.
    Li S; Yang Z; Shen J; Shan J; Qian C
    Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.
    Nagle SJ; Garfall AL; Stadtmauer EA
    Cancer J; 2016; 22(1):27-33. PubMed ID: 26841014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing the toxicities of CAR T-cell therapy.
    Neelapu SS
    Hematol Oncol; 2019 Jun; 37 Suppl 1():48-52. PubMed ID: 31187535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
    Darowski D; Kobold S; Jost C; Klein C
    MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in off-the-shelf CAR T-cell therapy.
    Benjamin R
    Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953
    [No Abstract]   [Full Text] [Related]  

  • 11. Paving New Roads for CARs.
    Hyrenius-Wittsten A; Roybal KT
    Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
    Gauthier J; Turtle CJ
    Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-Cell Receptor-Based Immunotherapy for Hematologic Malignancies.
    Biernacki MA; Brault M; Bleakley M
    Cancer J; 2019; 25(3):179-190. PubMed ID: 31135525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR-T cells: the Chinese experience.
    Wang L; Tan Su Yin E; Zhao H; Ni F; Hu Y; Huang H
    Expert Opin Biol Ther; 2020 Nov; 20(11):1293-1308. PubMed ID: 32605454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T-cell therapy: Full speed ahead.
    Sermer D; Brentjens R
    Hematol Oncol; 2019 Jun; 37 Suppl 1():95-100. PubMed ID: 31187533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of T-Cell Engaging Immunotherapy Complications.
    Varadarajan I; Lee DW
    Cancer J; 2019; 25(3):223-230. PubMed ID: 31135530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
    Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
    Front Immunol; 2021; 12():611366. PubMed ID: 33708205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Kallam A; Vose JM
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):751-757. PubMed ID: 31648957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.